TR
Tarek Rabah
President and Chief Executive Officer, Otsuka North America Pharmaceutical Business
OtsukaTherapeutic Areas
Otsuka Pipeline
| Drug | Indication | Phase |
|---|---|---|
| VOYXACT® (sibeprenlimab-szsi) | Undisclosed CNS condition | Phase not specified (Data presented) |
| Repinatrabit | Phenylketonuria (PKU) | Open-Label Extension |
| Undisclosed NDA Candidate | Undisclosed | NDA Submitted |
| Transcend Therapeutics Portfolio | Neuropsychiatry | Acquisition announced |